Antisense News and Research RSS Feed - Antisense News and Research

Antisense is the non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA synthesis.
Trends, R&D progress, and predicted revenues in RNAi therapies

Trends, R&D progress, and predicted revenues in RNAi therapies

When will RNAi therapies reach the market? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there. [More]
Isis Pharmaceuticals receives $2.15 million milestone payment to advance ISIS-SMN Rx study in children with SMA

Isis Pharmaceuticals receives $2.15 million milestone payment to advance ISIS-SMN Rx study in children with SMA

Isis Pharmaceuticals, Inc. announced today that it has earned a $2.15 million milestone payment from Biogen related to advancing the ongoing pivotal Phase 3 study (CHERISH) evaluating ISIS-SMN Rx in children with spinal muscular atrophy (SMA). [More]
Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS). [More]
iCo Therapeutics declares voting and election results from its 2015 Annual Meeting of Shareholders

iCo Therapeutics declares voting and election results from its 2015 Annual Meeting of Shareholders

iCo Therapeutics, today announced that all nominees listed in the management information circular dated June 1, 2015 were elected as directors at its 2015 Annual Meeting of Shareholders, held earlier today, June 26 2015. [More]
Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 study in children with SMA

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 study in children with SMA

Isis Pharmaceuticals, Inc. today provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMN Rx and are continuing to receive treatment in an open-label extension (OLE) study. [More]
Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 clinical study in infants with Type I SMA

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 clinical study in infants with Type I SMA

Isis Pharmaceuticals, Inc. today provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMN Rx in infants with Type I spinal muscular atrophy (SMA). [More]
iCo Therapeutics reports financial results for first quarter 2015

iCo Therapeutics reports financial results for first quarter 2015

iCo Therapeutics, today reported financial results for the quarter ended March 31, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). [More]
Bayer to further develop ISIS-FXIRx antisense investigational drug for thrombosis prevention

Bayer to further develop ISIS-FXIRx antisense investigational drug for thrombosis prevention

Bayer HealthCare has entered into an exclusive license agreement with Isis Pharmaceuticals, Inc. on ISIS-FXIRx, an antisense investigational drug in clinical development for the prevention of thrombosis. Under the agreement Bayer will further develop and commercialize ISIS-FXIRx in areas of high unmet medical need. [More]
Study explores innovative approach to identifying successful treatment for HER2+ breast cancer

Study explores innovative approach to identifying successful treatment for HER2+ breast cancer

Ahmad M. Khalil, PhD, knew the odds were against him -- as in thousands upon thousands to one. Yet he and his team never wavered from their quest to identify the parts of the body responsible for revving up one of the most aggressive forms of breast cancer, HER2+. This month in Breast Cancer Research and Treatment, Khalil and his colleagues at Case Western Reserve University proved the power of persistence; from a pool of more than 30,000 possibilities, they found 38 genes and molecules that most likely trigger HER2+ cancer cells to spread. [More]
Researchers provide new clues, mechanisms to understand functions of 'rebel' DNA in cancer

Researchers provide new clues, mechanisms to understand functions of 'rebel' DNA in cancer

Genes usually always be expressed as in Western writing: from left to right on the white canvas of our DNA. So when we speak of the activity of our genome, in fact we are referring to the expression of genes in this sense of the double-stranded DNA. [More]
Isis Pharmaceuticals announces positive results from ISIS-ANGPTL3Rx Phase 1 study

Isis Pharmaceuticals announces positive results from ISIS-ANGPTL3Rx Phase 1 study

Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-ANGPTL3Rx. In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 (ANGPTL3) of up to 93 percent with a mean reduction of up to 84 percent from baseline (p<0.001). [More]
Researchers reveal how malaria parasite deploys genetic trickery to escape immune system attack

Researchers reveal how malaria parasite deploys genetic trickery to escape immune system attack

Up to one million people -- mainly pregnant woman and young children -- are killed each year by the Plasmodium falciparum parasite, which causes the most devastating form of human malaria. [More]
Beckman Coulter Genomics Introduces a Scalable RNA-seq service line for processing intact and degraded RNA samples

Beckman Coulter Genomics Introduces a Scalable RNA-seq service line for processing intact and degraded RNA samples

This fully automated sample preparation pipeline delivers consistent results run after run, reducing user variability and bias and allows processing of a large amount of samples with reduced turnaround time relative to manual library construction. [More]
Isis Pharmaceuticals announces positive results from Phase 1 study of ISIS-PKK Rx for HAE treatment

Isis Pharmaceuticals announces positive results from Phase 1 study of ISIS-PKK Rx for HAE treatment

Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE). [More]
Experimental Ebola virus medication shows promise in monkeys

Experimental Ebola virus medication shows promise in monkeys

An experimental medication that targets a protein in Ebola virus called VP24 protected 75% of a group of monkeys that were studied from Ebola virus infection, according to new research conducted by the U.S. Army, in collaboration with Sarepta Therapeutics, Inc. [More]
Isis receives $5 million from Biogen Idec to develop drugs for neurological disorders

Isis receives $5 million from Biogen Idec to develop drugs for neurological disorders

Isis Pharmaceuticals, Inc. announced today it has earned a $5 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder under its broad strategic collaboration with Biogen Idec to develop drugs to treat patients with neurological disorders. [More]
Vanderbilt researchers find link between the biological clock and Angelman syndrome

Vanderbilt researchers find link between the biological clock and Angelman syndrome

Monitoring participants' biological clocks may be the quickest way to determine the effectiveness of experimental drugs currently under development to treat Angelman syndrome: a debilitating genetic disorder that occurs in more than one in every 15,000 live births. [More]
Isis receives $10 million from Biogen Idec to begin IND-supporting studies of ISIS-BIIB4 Rx

Isis receives $10 million from Biogen Idec to begin IND-supporting studies of ISIS-BIIB4 Rx

Isis Pharmaceuticals, Inc. announced today that it has earned a $10 million milestone payment from Biogen Idec for initiating the investigational new drug (IND)-supporting studies of ISIS-BIIB4 Rx. [More]
Study demonstrates therapeutic potential of new class of synthetic oligonucleotides for DMD treatment

Study demonstrates therapeutic potential of new class of synthetic oligonucleotides for DMD treatment

Research efforts associating scientists from the CNRS, UVSQ and INSERM within the Laboratoire END-ICAP, working in collaboration with a team from the University of Bern, has demonstrated the therapeutic potential of a new class of synthetic oligonucleotides in the treatment of Duchenne muscular dystrophy (DMD) using RNA "surgery". [More]
Bern researchers develop active substance for treating Duchenne muscular dystrophy

Bern researchers develop active substance for treating Duchenne muscular dystrophy

Duchenne muscular dystrophy is a congenital disease which causes muscle degeneration and eventual death in teenagers. Recently, researchers from Bern developed an active substance, which they together with an international team tested successfully. [More]
Advertisement
Advertisement